Dyadic (AMEX:DIL)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Dyadic Charts. Click Here for more Dyadic Charts.](/p.php?pid=staticchart&s=A%5EDIL&p=8&t=15)
Dyadic International, Inc. (AMEX:DIL), a biotechnology company,
announced today that Mark Emalfarb, Dyadic’s
President and Chief Executive Officer, will make a presentation at the
Sanders Morris Harris Investor Growth Conference to be held in New York
City at the Omni Berkshire Place, 21 East 52nd Street at Madison Avenue,
on October 23-24, 2006. Mr. Emalfarb's presentation is scheduled for
October 23 at 10:00 a.m. EDT.
A simultaneous webcast of the presentation may be accessed by clicking
the webcast link at www.dyadic.com.
A replay will be available for 30 days at the same internet address.
Mr. Emalfarb plans to discuss Dyadic's progress in the development of
its proprietary enabling platform technologies, which are broadly
applicable for the discovery, development and large-scale production of
new, improved and/or more affordable products in three core business
areas:
Biorefineries, including the Company’s
recent advances in the development of its patented and proprietary
enzyme mixtures to make abundant low-cost sugars from agricultural
plant materials. Sugars can be used in place of petroleum to produce
ethanol, plastics and polymers in a variety of manufacturing and
refining processes.
Biosciences, updating Dyadic's efforts to leverage its patented
C1 Host Technology to facilitate more efficient discovery, development
and production of new, improved and/or more affordable human
antibodies, as well as other protein drugs; and,
Enzymes, detailing the Company’s
progress in expanding its Enzyme Business beyond textiles to larger
and more profitable markets including pulp and paper and animal feed.
About Dyadic
Dyadic International, Inc., based in Jupiter, Florida, with operations
in the United States of America, Hong Kong and mainland China, Poland
and The Netherlands, is engaged in the development, manufacture and sale
of biological products using a number of proprietary fungal strains to
produce enzymes and other biomaterials, principally focused on a system
for protein production based on the patented Chrysosporium lucknowense
fungus, known as C1. Dyadic is applying its technologies to produce
enzymes for use in converting various agricultural products (e.g. corn)
and waste products (e.g. switch grass, wheat straw, sugar cane bagasse,
etc.) into fermentable sugars, which can then be used in the production
of traditional and cellulosic ethanol as well as other products
currently derived from petroleum. Dyadic's C1 technology also is being
developed to facilitate the discovery, development and large-scale
production of human antibodies and other high-value therapeutic
proteins. Dyadic currently sells more than 45 liquid and dry enzyme
products to more than 200 industrial customers in approximately 50
countries for the textile, pulp & paper, animal feed, alcohol, starch,
and food and beverage industries.
Cautionary Statement for Forward-Looking Statements
Certain statements contained in this press release are
"forward-looking statements." These forward-looking
statements involve risks and uncertainties that could cause our actual
results, performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by such
forward-looking statements. For a discussion of these risks and
uncertainties, please see our filings from time to time with the
Securities and Exchange Commission, which are available free of charge
on the SEC's web site at http://www.sec.gov,
including our Annual Report on Form 10-KSB for the year ended December
31, 2005, and our subsequent filings with the SEC. Except as
required by law, we expressly disclaim any intent or obligation to
update any forward-looking statements.
Dyadic International, Inc. (AMEX:DIL), a biotechnology company,
announced today that Mark Emalfarb, Dyadic's President and Chief
Executive Officer, will make a presentation at the Sanders Morris
Harris Investor Growth Conference to be held in New York City at the
Omni Berkshire Place, 21 East 52nd Street at Madison Avenue, on
October 23-24, 2006. Mr. Emalfarb's presentation is scheduled for
October 23 at 10:00 a.m. EDT.
A simultaneous webcast of the presentation may be accessed by
clicking the webcast link at www.dyadic.com. A replay will be
available for 30 days at the same internet address.
Mr. Emalfarb plans to discuss Dyadic's progress in the development
of its proprietary enabling platform technologies, which are broadly
applicable for the discovery, development and large-scale production
of new, improved and/or more affordable products in three core
business areas:
-- Biorefineries, including the Company's recent advances in the
development of its patented and proprietary enzyme mixtures to
make abundant low-cost sugars from agricultural plant
materials. Sugars can be used in place of petroleum to produce
ethanol, plastics and polymers in a variety of manufacturing
and refining processes.
-- Biosciences, updating Dyadic's efforts to leverage its
patented C1 Host Technology to facilitate more efficient
discovery, development and production of new, improved and/or
more affordable human antibodies, as well as other protein
drugs; and,
-- Enzymes, detailing the Company's progress in expanding its
Enzyme Business beyond textiles to larger and more profitable
markets including pulp and paper and animal feed.
About Dyadic
Dyadic International, Inc., based in Jupiter, Florida, with
operations in the United States of America, Hong Kong and mainland
China, Poland and The Netherlands, is engaged in the development,
manufacture and sale of biological products using a number of
proprietary fungal strains to produce enzymes and other biomaterials,
principally focused on a system for protein production based on the
patented Chrysosporium lucknowense fungus, known as C1. Dyadic is
applying its technologies to produce enzymes for use in converting
various agricultural products (e.g. corn) and waste products (e.g.
switch grass, wheat straw, sugar cane bagasse, etc.) into fermentable
sugars, which can then be used in the production of traditional and
cellulosic ethanol as well as other products currently derived from
petroleum. Dyadic's C1 technology also is being developed to
facilitate the discovery, development and large-scale production of
human antibodies and other high-value therapeutic proteins. Dyadic
currently sells more than 45 liquid and dry enzyme products to more
than 200 industrial customers in approximately 50 countries for the
textile, pulp & paper, animal feed, alcohol, starch, and food and
beverage industries.
Cautionary Statement for Forward-Looking Statements
Certain statements contained in this press release are
"forward-looking statements." These forward-looking statements involve
risks and uncertainties that could cause our actual results,
performance or achievements to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. For a discussion of these risks and
uncertainties, please see our filings from time to time with the
Securities and Exchange Commission, which are available free of charge
on the SEC's web site at http://www.sec.gov, including our Annual
Report on Form 10-KSB for the year ended December 31, 2005, and our
subsequent filings with the SEC. Except as required by law, we
expressly disclaim any intent or obligation to update any
forward-looking statements.